TUCSON, ARIZONA, DECEMBER 11, 2023 – Avery Therapeutics, Inc., a privately held, pre-clinical stage therapeutics company, developing therapeutics for diseases of aging, inflammation and fibrosis announces a publication in Nature Communications Biology, dated November 24, 2023. The article, titled “Biologically derived epicardial patch induces macrophage mediated pathophysiologic repair in chronically infarcted swine hearts,” demonstrates a novel approach in the treatment of chronic heart failure (CHF).
The study sheds light on an immunomodulatory allogeneic biologic being developed by the company. “I am humbled by the work of our team. These data represent something truly exciting and we look forward to pioneering our platform into the clinic,” said Avery Therapeutics’ CEO Jordan Lancaster, Ph.D.
With nearly 65 million people globally suffering from CHF and no targeted treatment for the underlying pathology, Avery Therapeutics presents a promising solution. Avery’s biologic has been extensively tested in various pre-clinical models of chronic heart failure. “These data demonstrate our ability to improve cardiac function and cardiac structure. Clinically, these results would mean clear benefit to the patient,” said Steven Goldman, M.D., a co-author of the paper and Avery’s Chief Medical Officer.
Key findings of the study include:
- Restoration of Left Ventricular Contractility: After six months of treatment in swine, the biologic successfully restores left ventricular contractility without constrictive physiology.
- Reversal of Maladaptive Remodeling: The biologic partially reverses maladaptive left ventricular and right ventricular remodeling in swine hearts.
- Improved Blood Flow and Left Ventricular Function: The biologic increases blood flow to the damaged heart and enhances left ventricular function in the rat model.
- Enhanced Exercise Tolerance: Swine treated with the biologic demonstrate increased exercise tolerance.
- Immunomodulatory Effect: Transcriptomic data opbtained through digital spatial profiling in mice reveals that the biologic induces a CD45pos immune cell response, leading to the infiltration of macrophages with high expression of macrophage polarization to the anti-inflammatory reparative M2 phenotype.
The study’s results suggest the potential use of immunomodulatory therapies for the treatment of chronic inflammatory diseases, extending beyond ischemic CHF.
The full article is available in Nature Communications Biology at: https://doi.org/10.1038/s42003-023-05564-w
Avery Therapeutics, Inc. remains committed to advancing regenerative medicine and looks forward to translating these groundbreaking findings into transformative therapies for patients.
Avery Media Contact:
Dan Ross
About Avery Therapeutics, Inc.
Avery Therapeutics, Inc. is developing therapeutics to redirect the immune system to address diseases of aging, inflammation, and fibrosis.